Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
veliparib + capecitabine + oxaliplatin
- Development stage
- Phase 1
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Veliparib (ABT-888) is an oral small molecule inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes 1 and 2. It is being evaluated in combination with the chemotherapy agents capecitabine (a fluoropyrimidine carbamate) and oxaliplatin (a platinum-based antineoplastic) for the treatment of various advanced solid tumors, including gastrointestinal malignancies like pancreatic and gastric adenocarcinomas, as well as colorectal and ovarian cancers. The combination aims to enhance the cytotoxic effects of chemotherapy by blocking PARP-mediated DNA repair, particularly in tumors with homologous recombination deficiencies or BRCA mutations. This specific regimen has been studied in Phase 1 trials sponsored by the National Cancer Institute (NCI).
- Other names
- ABT-888 + capecitabine + oxaliplatin
02
Targets
DNAPARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)TS (Thymidylate synthase)Pol II (RNA polymerase II elongation factors)
Beyond the preview
Go deeper on veliparib + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on veliparib + capecitabine + oxaliplatin.